IHC Marker-CEA Test: Booking, Price, and Results
About IHC Marker-CEA Test
| Field | Value |
|---|---|
| Also Known As | CEA IHC, Carcinoembryonic Antigen Immunohistochemistry, CEA Immunostain, CEACAM5 IHC, CD66e |
| Sample Type | Formalin-fixed, paraffin-embedded (FFPE) tissue block |
| Fasting Required | No |
| Report Time | 7 days |
| Recommended For | All genders, adults with suspected or confirmed adenocarcinoma |
| Price | Starting at ₹1,920 |
What is an IHC Marker-CEA Test?
The IHC marker-CEA test detects carcinoembryonic antigen (CEA) protein directly in a tissue sample. CEA is a glycoprotein normally present in foetal tissue but found at very low levels in healthy adults. When CEA appears in significant amounts in adult tissue, it can indicate certain cancers, particularly those arising from glandular cells (adenocarcinomas). The test is also known as CEA immunohistochemistry or CEA Immunostain. It requires a tissue biopsy or a surgical specimen rather than a blood sample.
What Does an IHC Marker-CEA Test Measure?
The IHC marker-CEA procedure examines tissue sections stained with antibodies that specifically bind CEA. A pathologist then studies the stained slides under a microscope and evaluates three key aspects.
| What Is Evaluated | What It Means |
|---|---|
| CEA protein expression | Whether CEA protein is present in the tissue cells |
| Staining pattern | Where the protein appears: at the cell surface (membranous), inside the cell (cytoplasmic), or at the cell border (apical) |
| Staining intensity | How strongly the cells react: none, weak, intermediate, or strong |
Together, these findings help pathologists determine the type and likely origin of a tumour.
Why is an IHC Marker-CEA Test Done?
Doctors order this test when tissue examination reveals abnormal cells that need further characterisation. It is a specialised oncology investigation, not a routine screening tool.
Common Symptoms That May Require This Test
A doctor may recommend this test after a biopsy is taken from a patient presenting with the following:
- Unexplained weight loss and persistent fatigue
- A palpable lump or mass in the abdomen, chest, or elsewhere
- Changes in bowel habits lasting several weeks
- Persistent cough or breathing difficulty with abnormal imaging findings
- Abnormal findings on a prior histopathology or biopsy report
- Suspected spread (metastasis) of cancer from an unknown primary site
Conditions This Test Can Help Detect
The IHC marker-CEA test helps identify or confirm the following conditions:
- Colorectal cancer and other gastrointestinal cancers (stomach, oesophagus, pancreas, gallbladder)
- Pulmonary adenocarcinoma (a type of lung cancer)
- Thyroid gland cancers
- Adenocarcinomas of the ovary, endocervix, salivary gland, and urachus
- Breast cancer (certain subtypes)
- Metastatic adenocarcinoma of unknown primary origin
How to Prepare and What to Expect
No special physical preparation is needed by the patient for this test. However, providing the right documentation is important for accurate interpretation.
Do You Need to Fast?
No fasting is required. This test is performed on a tissue sample collected during a biopsy or surgery. The patient does not need to modify diet or fluid intake before sample collection.
Practical Tips Before Your Test
The following steps will help ensure the test runs smoothly:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Carry your previous histopathology or biopsy reports, especially if this is a follow-up or second opinion
- Inform your doctor about all current medications
- Provide any relevant imaging reports (CT scan, PET scan, MRI) to your treating doctor before submission
Step-by-Step Procedure
The laboratory processes the tissue sample through the following steps:
- A surgeon or pathologist collects the tissue through a biopsy or surgical removal and preserves it in formalin to maintain cellular structure.
- The preserved tissue is embedded in paraffin wax to form a solid block (FFPE block), which is then submitted to the laboratory.
- Laboratory technicians cut extremely thin slices (approximately 4-5 microns) from the block and mount them on glass slides.
- The slides undergo antigen retrieval, a heat or enzyme-based process that exposes CEA proteins that fixation may have masked.
- Specific antibodies targeting CEA are applied to the tissue sections and allowed to bind to their target protein.
- A secondary detection system amplifies the signal, creating a visible colour reaction.
- A pathologist then examines the stained slides under a microscope and prepares a report.
Factors That Can Affect Accuracy
The following factors may influence the quality of results:
- Improper or delayed fixation of the tissue sample in formalin
- Over-fixation or under-fixation, both of which affect protein preservation
- Poor tissue processing or sectioning technique
- Use of degraded or improperly stored reagents and antibodies
- Incomplete or missing clinical history provided to the pathologist
Understanding Your IHC Marker-CEA Test Results
Results from the IHC marker-CEA test are interpreted by a qualified pathologist as part of a broader clinical assessment. The report describes staining intensity, pattern, and the proportion of cells that are positive. Below is a general guide to what results may indicate.
| Result | Interpretation |
|---|---|
| Negative | No CEA protein detected; expected finding in normal adult tissue |
| Positive (weak or focal) | Low-level CEA expression in a small number of cells |
| Positive (moderate to strong, diffuse) | Significant CEA expression across many cells, suggestive of adenocarcinoma |
These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain factors may affect how results are read or interpreted.
- Smoking and non-cancerous conditions such as liver disease or inflammatory bowel disease can elevate CEA levels in the body, which may influence tissue expression in some cases.
- Technical variables, including tissue fixation time and the age of the paraffin block, can occasionally affect staining intensity, potentially leading to weaker or inconsistent results. Your pathologist will account for these factors when preparing the report.
How to Maintain Healthy Levels
These general wellness tips support overall health during and after cancer investigations:
- Maintain a balanced diet with adequate fruits, vegetables, and whole grains to support immune function
- Avoid smoking, as it is associated with elevated CEA and increased cancer risk
- Attend all scheduled follow-up appointments with your oncologist or treating specialist
Lupin Diagnostics IHC Marker-CEA Test Price
The IHC marker-CEA test cost at Lupin Diagnostics starts at ₹1,920. This test requires a visit to a Lupin Diagnostics centre or submission of the FFPE tissue block; home collection is not available.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 1920 |
| CHENNAI | 1920 |
| HYDERABAD | 1920 |
| KOLKATA | 1920 |
| NAVI MUMBAI | 1920 |
| PUNE | 1920 |
Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book your IHC marker-CEA test online:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time to submit a sample or block.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The IHC marker-CEA test detects CEA protein directly within tissue cells, allowing a pathologist to localise it to specific tumour cells. A blood CEA test measures the amount of CEA circulating in the bloodstream. The tissue-based IHC test is used for diagnosis and tumour characterisation, while the blood test is used for monitoring treatment response over time.
IHC testing examines the actual cells within a tumour or abnormal tissue, revealing which proteins are present and where they are located. This information helps pathologists determine the type and likely origin of a cancer, which cannot be established from a blood sample alone.
The tissue sample is collected by a surgeon or pathologist through a biopsy or surgical removal of an abnormal mass. Once collected, it is preserved in formalin and processed into an FFPE block before being sent to the laboratory.
The report is typically ready within 7 days of the laboratory receiving the tissue block. Turnaround time may vary slightly depending on sample quality and any additional stains required.
No, a positive result alone is not sufficient for a definitive cancer diagnosis. The findings must be interpreted alongside clinical history, imaging studies, and other pathological markers. Your treating oncologist and pathologist will assess all available information before reaching a conclusion.
No. This test is not designed for screening the general population. It is ordered after a biopsy or surgical specimen already shows abnormal or suspicious tissue findings that require further characterisation.
A histopathologist prepares the initial report. Depending on the findings, an oncologist, surgical oncologist, or gastroenterologist will then discuss the results with the patient and recommend next steps as part of the overall treatment plan.
IHC Marker-CEA Test: Booking, Price, and Results
